Oragenics, Inc. (OGEN), on Tuesday announced a strategic partnership with BRAINBox Solutions to develop the first intranasal therapy for mild traumatic brain injury or mTBI, also known as concussion.
The collaboration aims to create a comprehensive "trigger-to-treat" platform, combining BRAINBox's advanced diagnostic technology with Oragenics' intranasal therapeutic candidate, ONP-002.
BRAINBox's proprietary diagnostic system uses neurological biomarkers, neuropsychological assessments, and AI-driven analytics to provide rapid and accurate concussion diagnoses.
Oragenics' ONP-002, a neurosteroid therapeutic, has shown promise in preclinical studies to mitigate brain injury effects and support recovery.
The goal is to offer a solution that addresses both the identification and treatment of mTBI, improving patient outcomes.
BRAINBox's diagnostic tools will play a critical role in Oragenics' upcoming Phase IIa clinical trials, allowing for precise patient selection and real-time monitoring of therapeutic efficacy.
This partnership represents a major step forward in concussion care, providing the potential for faster intervention and better long-term recovery for concussion patients.
Currently, OGEN is trading at $0.28 down by 0.52%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.